Filtered By:
Source: Heart Rhythm
Condition: Atrial Fibrillation
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 356 results found since Jan 2013.
Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden
In patients with cardiac implanted electronic devices (CIEDs) detection of new atrial fibrillation (AF) is associated with an increased risk of stroke.
Source: Heart Rhythm - November 6, 2017 Category: Cardiology Authors: Giuseppe Boriani, Taya V. Glotzer, Paul D. Ziegler, Mirko De Melis, Lorenza Mangoni di S. Stefano, Milan Sepsi, Maurizio Landolina, Maurizio Lunati, Thorsten Lewalter, A. John Camm Source Type: research
Atrial fibrillation and cognitive decline: Another piece for a big puzzle
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its prevalence is increasing over time.1,2 AF is associated with an increased risk of stroke,3 heart failure,4 and death.5 –7 In recent years, evidence has emerged to indicate that AF is associated with another growing public health problem: cognitive impairment and dementia.8 Although the evidence is compelling, existing studies suffer from several limitations, such as reliance on the Mini-Mental State Examination, c ross-sectional design, and lack of attention to domain-specific changes.
Source: Heart Rhythm - October 10, 2017 Category: Cardiology Authors: Lin Y. Chen, Win-Kuang Shen Tags: Editorial Commentary Source Type: research
Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients treated with vitamin K antagonists: A review
Identifying patients who are likely to achieve and maintain a therapeutic INR when prescribed a vitamin K antagonist (VKA) for stroke prevention in atrial fibrillation (AF) and venous thromboembolism (VTE) is challenging. The SAMe-TT2R2 score was developed based on common clinical factors that can highlight patients who may be unable to achieve and maintain good anticoagulation control and for whom a ‘trial of warfarin’ would be inadvisable. This review summarises the main published prospective and retrospective studies that have validated the SAMe-TT2R2 score in AF and VTE patients treated with a VKA and how the SAMe-...
Source: Heart Rhythm - November 24, 2017 Category: Cardiology Authors: Hanis Zulkifly, Gregory Y.H. Lip, Deirdre A. Lane Source Type: research
Mining the electronic medical record in patients with atrial fibrillation
I found several interesting nuggets of information in the new atrial fibrillation (AF) and stroke analysis from Patel et al1 published in this issue of HeartRhythm, starting with their use of the electronic medical record (EMR) to ask clinical questions. Most of us have a love-hate relationship with our EMR, but the undeniable truth is that it is here to stay. As you invest another late evening or the weekend catchi ng up with your EMR, how often have you wondered whether you can put all this documentation to scientific use? Certainly this is a laudable goal, but, in real life, easier said than done.
Source: Heart Rhythm - February 19, 2018 Category: Cardiology Authors: Sumeet S. Chugh Tags: Editorial Commentary Source Type: research
Does CHA2DS2-VASc Score reliably predict atrial arrhythmias? Analysis of a nationwide database of Remote Monitoring data daily transmitted from Cardiac Implantable Electronic Devices
CHA2DS2-VASc is a validated score for predicting stroke in patients with atrial fibrillation (AF).
Source: Heart Rhythm - February 22, 2018 Category: Cardiology Authors: Giovanni Rovaris, Francesco Solimene, Antonio D ’Onofrio, Gabriele Zanotto, Renato P. Ricci, Tiziana Mazzella, Saverio Iacopino, Paolo Della Bella, Giampiero Maglia, Gaetano Senatore, Fabio Quartieri, Mauro Biffi, Antonio Curnis, Valeria Calvi, Antonio Source Type: research
Is A Little Atrial Fibrillation Still Too Much?
Atrial fibrillation (AF) is most often viewed as a dichotomous variable, one that is either entirely present or absent. Guidelines support this perspective by recommending anticoagulation based on underlying stroke risk without regard to AF “type”, duration, or burden.1 The use of cardiac monitoring, however, has allowed us to quantify AF and associate outcomes with various arrhythmia characteristics.2, 3 These types of studies have raised legitimate doubts as to whether the 30 second threshold used to define AF is associated with meaningful consequences and have created equipoise for sub-clinical AF episodes lasting minutes to hours.
Source: Heart Rhythm - February 24, 2018 Category: Cardiology Authors: Rod Passman Source Type: research
Does the CHA2DS2-VASc score reliably predict atrial arrhythmias? Analysis of a nationwide database of remote monitoring data transmitted daily from cardiac implantable electronic devices
CHA2DS2-VASc is a validated score for predicting stroke in patients with atrial fibrillation (AF).
Source: Heart Rhythm - February 22, 2018 Category: Cardiology Authors: Giovanni Rovaris, Francesco Solimene, Antonio D'Onofrio, Gabriele Zanotto, Renato P. Ricci, Tiziana Mazzella, Saverio Iacopino, Paolo Della Bella, Giampiero Maglia, Gaetano Senatore, Fabio Quartieri, Mauro Biffi, Antonio Curnis, Valeria Calvi, Antonio Rap Source Type: research
Is a little atrial fibrillation still too much?
Atrial fibrillation (AF) is most often viewed as a dichotomous variable, one that is either entirely present or absent. Guidelines support this perspective by recommending anticoagulation based on underlying stroke risk without regard to AF “type,” duration, or burden.1 The use of cardiac monitoring, however, has allowed us to quantify AF and associate outcomes with various arrhythmia characteristics.2,3 These types of studies have raised legitimate doubts as to whether the 30-second threshold used to define AF is associated with m eaningful consequences and have created equipoise for subclinical AF episodes lasting minutes to hours.
Source: Heart Rhythm - February 24, 2018 Category: Cardiology Authors: Rod Passman Tags: Editorial Commentary Source Type: research
Does the CHA2DS2-VASc score reliably predict atrial arrhythmias? Analysis of a nationwide database of remote monitoring data transmitted daily from cardiac implantable electronic devices
CHA2DS2-VASc is a validated score for predicting stroke in patients with atrial fibrillation (AF).
Source: Heart Rhythm - February 22, 2018 Category: Cardiology Authors: Giovanni Rovaris, Francesco Solimene, Antonio D'Onofrio, Gabriele Zanotto, Renato P. Ricci, Tiziana Mazzella, Saverio Iacopino, Paolo Della Bella, Giampiero Maglia, Gaetano Senatore, Fabio Quartieri, Mauro Biffi, Antonio Curnis, Valeria Calvi, Antonio Rap Source Type: research
Mining the electronic medical record in patients with atrial fibrillation
I found several interesting nuggets of information in the new atrial fibrillation (AF) and stroke analysis from Patel et al1 published in this issue of HeartRhythm, starting with their use of the electronic medical record (EMR) to ask clinical questions. Most of us have a love-hate relationship with our EMR, but the undeniable truth is that it is here to stay. As you invest another late evening or the weekend catchi ng up with your EMR, how often have you wondered whether you can put all this documentation to scientific use? Certainly this is a laudable goal, but, in real life, easier said than done.
Source: Heart Rhythm - February 19, 2018 Category: Cardiology Authors: Sumeet S. Chugh Tags: Editorial Commentary Source Type: research
Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A review
Identifying patients who are likely to achieve and maintain a therapeutic international normalized ratio when prescribed a vitamin K antagonist for stroke prevention in atrial fibrillation (AF) and venous thromboembolism (VTE) is challenging. The SAMe-TT2R2 score was developed on the basis of common clinical factors that can highlight patients who may be unable to achieve and maintain good anticoagulation control and for whom a “trial of warfarin” would be inadvisable. This review summarizes the main published prospective and retrospective studies that have validated the SAMe-TT2R2 score in patients with AF and VTE tre...
Source: Heart Rhythm - November 24, 2017 Category: Cardiology Authors: Hanis Zulkifly, Gregory Y.H. Lip, Deirdre A. Lane Tags: Contemporary Review Source Type: research
Screening for Atrial Fibrillation using Smartphone-based Technology and Layperson Volunteers: High-Tech Meets Community Participatory Research for the Best of Both Worlds
Atrial fibrillation (AF), usually asymptomatic and not previously-diagnosed, increases risk of stroke by five times1 and accounts for 15-25% of strokes. 2 Asymptomatic AF is estimated to affect 600,000 Americans, with an estimated cost of 3 billion dollars per year.3 Just because we can identify a risk factor does not mean screening for it will save lives. AF, however, meets most criteria laid out in the World Health Organization ’s manifesto on screening, “Principles and Practice of Screening for Disease”.
Source: Heart Rhythm - July 4, 2018 Category: Cardiology Authors: Rachel Lampert Source Type: research
Silent cerebral embolism in cryoballoon ablation of atrial fibrillation: when details matter.
Although the clinically manifest stroke rate related to pulmonary vein isolation (PVI) is rare and currently
Source: Heart Rhythm - July 23, 2018 Category: Cardiology Authors: Jacopo Marazzato, Roberto De Ponti Source Type: research
EP News: Allied Professionals
Using data on patients in the United States Renal Data System (USRDS), Siontis et al (Circulation 2018; https://doi.org/10.1161/CIRCULATIONAHA.118.035418 [Epub ahead of print], PMID 29954737) sought to assess patterns of apixaban use and outcomes related to use of anticoagulants in patients with end-stage renal disease (ESRD) and atrial fibrillation (AF). As background, patient s with ESRD have both higher risk of bleeding and higher risk of stroke with AF. The Food and Drug Administration has approved updated labeling for the use of apixaban in patients with ESRD on the basis of a small pharmacokinetic study.
Source: Heart Rhythm - July 26, 2018 Category: Cardiology Authors: Erica S. Zado Tags: EP News Source Type: research
Defibrillation testing and clinical outcomes after implantable cardioverter defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial
The Shockless IMPLant Evaluation (SIMPLE) showed that defibrillation testing (DT) at the time of implantable cardioverter defibrillator (ICD) implant did not improve shock efficacy or reduce mortality. There are no data regarding the risk of complications, including stroke, among patients with atrial fibrillation (AF) who undergo DT.
Source: Heart Rhythm - July 28, 2018 Category: Cardiology Authors: Stefan Bogdan, Michael Glikson, Stuart J. Connolly, Jia Wang, Stefan H. Hohnloser, Ursula Appl, Jorg Neuzener, Philippe Mabo, Xavier Vinolas, Frederick Gadler, Lieselot van Erven, Josef Kautzner, Brandi Meeks, Janice Pogue, Jeff S. Healey Source Type: research
